M.A.C. Dimopoulos
Impact in
- Hematology top 0.01%
- Multiple Myeloma Research and Treatments
- Genetics top 0.02%
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 787
- Multiple Myeloma Research and Treatments 734
- Oncology 561
- Peptidase Inhibition and Analysis 171
- Cancer Treatment and Pharmacology 169
- Bone health and treatments 80
- Co-authors
- E Terpos (251 shared papers)Efstathios Kastritis (251 shared papers)Lia Angela Moulopoulos (71 shared papers)Raymond Alexanian (44 shared papers)Maria Gavriatopoulou (251 shared papers)Ioannis Ntanasis‐Stathopoulos (186 shared papers)Jesús F. San Miguel (85 shared papers)Dimitra Gika (83 shared papers)
- Journals
- Blood (255 papers)Annals of Oncology (63 papers)Journal of Clinical Oncology (46 papers)American Journal of Hematology (45 papers)HemaSphere (35 papers)
- Partner nations
- GreeceUnited StatesFrance
In The Last Decade
M.A.C. Dimopoulos
1.5k papers receiving 53.5k citations
M.A.C. Dimopoulos's Hit Papers
Peers
Comparison fields: 5 of 192
- Hematology 24.1k
- Genetics 8.6k
- Oncology 19.7k
- Pathology and Forensic Medicine 6.0k
- Molecular Biology 18.8k
Countries citing papers authored by M.A.C. Dimopoulos
This map shows the geographic impact of M.A.C. Dimopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.A.C. Dimopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.A.C. Dimopoulos more than expected).
Fields of papers citing papers by M.A.C. Dimopoulos
This network shows the impact of papers produced by M.A.C. Dimopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.A.C. Dimopoulos. The network helps show where M.A.C. Dimopoulos may publish in the future.
Co-authors
The 25 scholars most cited alongside M.A.C. Dimopoulos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.6k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Hematological findings and complications of COVID ‐19 Hit paper breakdown → | 2020 | 1210 |
| 2 | Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma Hit paper breakdown → | 2007 | 1149 |
| 3 | Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors Hit paper breakdown → | 2005 | 926 |
| 4 | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma Hit paper breakdown → | 1996 | 865 |
| 5 | New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes Hit paper breakdown → | 2012 | 709 |
| 6 | Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia Hit paper breakdown → | 2003 | 702 |
| 7 | Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 547 |
| 8 | Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† Hit paper breakdown → | 2021 | 531 |
| 9 | 1998 | 524 | |
| 10 | Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2018 | 391 |
| 11 | 2013 | 372 | |
| 12 | 2009 | 353 | |
| 13 | 2008 | 347 | |
| 14 | 2020 | 344 | |
| 15 | 2010 | 336 | |
| 16 | 1994 | 317 | |
| 17 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study Hit paper breakdown → | 2020 | 310 |
| 18 | Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial Hit paper breakdown → | 2017 | 303 |
| 19 | 2000 | 285 | |
| 20 | 2009 | 284 |
About M.A.C. Dimopoulos
M.A.C. Dimopoulos is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Pathology and Forensic Medicine, having authored 1.6k papers that have together received 55.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (734 papers), Protein Degradation and Inhibitors (239 papers), Chronic Lymphocytic Leukemia Research (181 papers), Peptidase Inhibition and Analysis (171 papers), Cancer Treatment and Pharmacology (169 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (137 papers), Lymphoma Diagnosis and Treatment (117 papers) and Bone health and treatments (80 papers). The work is most often cited by research in Hematology (24.1k citations), Genetics (8.6k citations), Oncology (19.7k citations), Pathology and Forensic Medicine (6.0k citations) and Molecular Biology (18.8k citations). M.A.C. Dimopoulos has collaborated with scholars based in Greece, United States and France. Frequent co-authors include E Terpos, Efstathios Kastritis, Lia Angela Moulopoulos, Raymond Alexanian, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Jesús F. San Miguel, Dimitra Gika, Christos Papadimitriou and Theodora Psaltopoulou. Their work appears in journals such as Blood, Annals of Oncology, Journal of Clinical Oncology, American Journal of Hematology and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.